"GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study"

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Güder, Gülmisal ^a,b   Brenner, Susanne ^b   Angermann, Christiane E ^b   Ertl, Georg ^b   Held, Matthias ^c   Sachs, Alfred P ^a   Lammers, Jan Willem ^a   Zanen, Pieter ^a   Hoes, Arno W ^a   Störk, Stefan ^b   Rutten, Frans H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c Missionsarztliche Klinik GmbH   (Germany)

Author keywords

COPD diagnosis; GOLD; Lower limit of normal; Validation

Indexed keywords

AGED; ARTICLE; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURES; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; EXPERT BASED DIAGNOSIS; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; GENERAL PRACTITIONER; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LOWER FIFTH PERCENTILE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CODING; PREDICTOR VARIABLE; PREVALENCE; PROSPECTIVE STUDY; RESIDUAL VOLUME; SPIROMETRY; STANDARD; CLASSIFICATION; COMPARATIVE STUDY; DIAGNOSTIC TEST; FORCED EXPIRATORY VOLUME; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TOTAL LUNG CAPACITY; VALIDATION STUDY; VITAL CAPACITY;

AGED; COHORT STUDIES; DIAGNOSTIC ERRORS; DIAGNOSTIC TESTS, ROUTINE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE STANDARDS; RESIDUAL VOLUME; RETROSPECTIVE STUDIES; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 84858076185     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-13     Document Type: Article

References (35)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349(9064):1498-1504. 10.1016/S0140-6736(96)07492-2, 9167458.
2. Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008, 14(2):176-185.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946. 10.1183/09031936.04.00014304, 15219010.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555. 10.1164/rccm.200703-456SO, 17507545.
5. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008, 63(12):1046-1051. 10.1136/thx.2008.098483, 18786983.
6. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163(5):1256-1276.
7. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002, 20(5):1117-1122. 10.1183/09031936.02.00023202, 12449163.
8. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003, 22(2):268-273. 10.1183/09031936.03.00075102, 12952259.
9. Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest 2007, 131(2):349-355. 10.1378/chest.06-1349, 17296632.
10. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005, 26(5):948-968. 10.1183/09031936.05.00035205, 16264058.
11. Moons KG, Grobbee DE. When should we remain blind and when should our eyes remain open in diagnostic studies?. J Clin Epidemiol 2002, 55(7):633-636. 10.1016/S0895-4356(02)00408-0, 12160909.
12. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005, 26(18):1887-1894. 10.1093/eurheartj/ehi291, 15860516.
13. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009, 11(12):1182-1188. 10.1093/eurjhf/hfp148, 19887495.
14. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993, 16:5-40.
15. Enright PL, Falaschetti E, Hankinson JL, Jenkins C, Jensen RL, Miller MR, Pedersen OF, Quanjer PH, Ruppel GL, Schouten JP, Stocks J, Swanney MP. The Pulmonaria Group CRO Interpreting Spirometric Test Results. The Pulmonaria Group CRO., http://www.spirxpert.com
16. Enright PL, Adams AB, Boyle PJ, Sherrill DL. Spirometry and maximal respiratory pressure references from healthy Minnesota 65- to 85-year-old women and men. Chest 1995, 108(3):663-669. 10.1378/chest.108.3.663, 7656613.
17. Falaschetti E, Laiho J, Primatesta P, Purdon S. Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J 2004, 23(3):456-463. 10.1183/09031936.04.00055204, 15065839.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33(1):159-174. 10.2307/2529310, 843571.
19. Vanbelle SAA. A bootstrap method for comparing correlated kappa coefficients. Journal of Statistical Computation & Simulation 2008, 78:1009-1015. 10.1080/00949650701410249, 22319141.
20. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians". Statistics in Medicine 2000, 19:1141-1164. 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F, 10797513.
21. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995, 142(12):1255-1264.
22. Calverley PM. The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med 2004, 170(3):211-212. discussion 214, 10.1164/rccm.2405008, 15280171.
23. Bellia V, Sorino C, Catalano F, Augugliaro G, Scichilone N, Pistelli R, Pedone C, Antonelli-Incalzi R. Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax 2008, 63(1):60-66. 10.1136/thx.2007.080572, 17702791.
24. Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, Wood KL. FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest 2006, 130(1):200-206. 10.1378/chest.130.1.200, 16840402.
25. Schermer TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, van Boxem TJ, Heijdra YF, van Weel C. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008, 32(4):945-952. 10.1183/09031936.00170307, 18550607.
26. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125(6):2309-2321. 10.1378/chest.125.6.2309, 15189956.
27. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300(20):2407-2416. 10.1001/jama.2008.717, 19033591.
28. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300(12):1439-1450. 10.1001/jama.300.12.1439, 18812535.
29. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination?. Eur J Heart Fail 2006, 8(7):706-711. 10.1016/j.ejheart.2006.01.010, 16531114.
30. Toljamo T, Kaukonen M, Nieminen P, Kinnula VL. Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care 28(1):41-46.
31. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006, 27(3):547-555. 10.1183/09031936.06.00062705, 16507855.
32. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997, 155(4):1283-1289.
33. Dykstra BJ, Scanlon PD, Kester MM, Beck KC, Enright PL. Lung volumes in 4,774 patients with obstructive lung disease. Chest 1999, 115(1):68-74. 10.1378/chest.115.1.68, 9925064.
34. National Collaborating Centre for Chronic Conditions. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004, 59(Suppl (1)):1-232. 1766028, 15041752.
35. Worster A, Carpenter C. Incorporation bias in studies of diagnostic tests: how to avoid being biased about bias. CJEM 2008, 10(2):174-175.